Effectiveness Of Topical Losartan In Corneal Scars.
Published 2024 - 42nd Congress of the ESCRS
Reference: PO165 | Type: Case Report | DOI: 10.82333/2q4t-hv98
Authors: Gabriela Utreras 1 , Nancy Jurado* 1
1CORNEA,HECAM,QUITO,Ecuador
Purpose
EVALUATE THE EFFECT OF TOPICAL LOSARTAN IN CORNEAL SCARRING FIBROSIS MEDIATED BY THE DEVELOPMENT OF MYOFIBROBLASTS AFTER TRAUMATIC INJURY, MICROBIAL INFECTIONS, SCARRING DISEASES AND SOME CORNEAL SURGERIES.
Setting
A CASE OF CORNEAL SCARRING DUE TO FUNGAL ULCER AND ANOTHER ONE WITH CORNEAL FIBROSIS AFTER CORNEAL RING EXTRUSION AT CARLOS ANDRADE MARIN HOSPITAL (QUITO ECUADOR) ARE PRESENTED
Report of case
- A 38 YEARS OLD MALE PATIENT PRESENTED MICOTIC ULCER AFTER FUSARIUM INFECTION IN THE LEFT EYE. UNCORRECTED DISTANCE VISUAL ACUITY (UDVA) WAS 20/200 AND CORRECTED DISTANCE VISUAL ACUITY WAS 20/100 THE PATIENT STARTED USE TOPICAL LOSARTAN 3.6MG/ML FOUR TIMES FOR DAY. AFTER ONE MONTH WE GOT UNCORRECTED DISTANCE VISUAL ACUITY (UDVA) WAS 20/80 AND CORRECTED DISTANCE VISUAL ACUITY WAS 20/40 AND A SIGNIFICANT REDUCTION OF CORNEAL HAZE WAS OBSERVED AT THE SLIT LAMP AND USING ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY.
- A 34 YEARS OLD MALE PATIENT PRESENTED CORNEAL FIBROSIS AFTER CORNEAL RING EXTRUSION INFECTION IN THE LEFT EYE. UNCORRECTED DISTANCE VISUAL ACUITY (UDVA) WAS 20/500 AND CORRECTED DISTANCE VISUAL ACUITY WAS 20/70 THE PATIENT STARTED USE TOPICAL LOSARTAN 3.6MG/ML FOUR TIMES FOR DAY. AFTER TWO MONTHS WE GOT UNCORRECTED DISTANCE VISUAL ACUITY (UDVA) WAS 20/400 AND CORRECTED DISTANCE VISUAL ACUITY WAS 20/40 AND A SIGNIFICANT REDUCTION OF CORNEAL HAZE WAS OBSERVED AT THE SLIT LAMP AND USING ANTERIOR SEGMENT OPTICAL COHERENCE TOMOGRAPHY.
Conclusion/Take home message
BY ANALYZING THE EFFECT OF THIS MEDICATION WE KNOW THAT THERE ARE TWO GROWTH FACTORS: TRANSFORMING GROWTH FACTOR (TGF) BETA-1 AND TGF BETA-2. WHICH INFLUENCE THE DEVELOPMENT OF MYOFIBROBLASTS. LOSARTAN CONSTITUTES A TGF BETA SIGNALING BARRIER BECAUSE IT INHIBITS AN EXTRACELLULAR SIGNAL TRANSDUCTION MOLECULE SIGNAL-REGULATED KINASE (ERK).